Recent Updates
Recently added Catalysts
FDMT Positive Sentiment

Uneek Mehra speaks on next-gen AAV panel at Chardan’s 7th Annual Genetic Medicines Conference

Wednesday, October 4, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Uneek Mehra, CFO and CBO of FDMT, participated in a panel at the Chardan 7th Annual Genetic Medicines Conference. The discussion centered on next-generation AAVs and the potential of synthetic AAV capsids in enhancing genetic medicines. Esteemed leaders in the field shared valuable insights aimed at improving patient outcomes.
Price reaction · baseline $11.695 (2023-10-04T14:39:00.000Z) · hit during market hours · clean, no other FDMT news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Uneek Mehra participated in a prestigious panel discussion.
  • The panel focused on advancements in synthetic AAV capsids.
  • Insights shared could benefit millions of patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration

Full Press Release Details

22,321 followers
• Report this post
Our CFO & CBO, Uneek Mehra , joined a panel alongside experts, Rick Modi, CEO of Affinia Therapeutics , Peter Anastasiou , CEO of Capsida Biotherapeutics , and Adrian Veres , MD, PhD, CSO of Dyno Therapeutics to discuss next-gen AAV’s at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday. It was an honor to join other esteemed leaders in the space in sharing our insights on how synthetic AAV capsids are unlocking the full potential of genetic medicines for millions of patients. #ChardanGMconf #CGMC2023 #geneticmedicines
• Copy
• LinkedIn
• Facebook
• X
To view or add a comment, sign in

Frequently Asked Questions

What was the focus of Uneek Mehra's panel discussion?

The panel focused on next-generation AAVs and the potential of synthetic AAV capsids.

Who joined Uneek Mehra on the panel?

Uneek Mehra was joined by leaders from Affinia Therapeutics, Capsida Biotherapeutics, and Dyno Therapeutics.

Where was the Chardan Genetic Medicines Conference held?

The conference took place in New York City.

What is the significance of synthetic AAV capsids?

Synthetic AAV capsids are unlocking the potential of genetic medicines for patients.

ShareAdd on Google
Tags: FDMT Viatris Investor Conferences Healthcare genetic medicines AAV capsids Chardan Conference Uneek Mehra
Last updated: Oct 4, 2023

Biotech snapshot

Cash runway
$431M liquidity · $23M/mo burn
~18 mo
Low dilution risk
Lead asset
4D-150 IVTPhase 3
Macular Neovascularization Secondary to Age-Related Macular Degeneration →

Catalyst track record

+128%
best trade around FDMT's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for FDMT.

See every catalyst's timing & PoA →